MedPath

Ibandronate

Generic Name
Ibandronate
Brand Names
Bondronat, Boniva, Bonviva, Iasibon, Ibandronic acid Accord, Ibandronic Acid Sandoz, Ibandronic Acid Teva
Drug Type
Small Molecule
Chemical Formula
C9H23NO7P2
CAS Number
114084-78-5
Unique Ingredient Identifier
UMD7G2653W
Background

Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid. It is used to prevent and treat postmenopausal osteoporosis. Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.

Ibandronate was granted FDA approval on 16 May 2003.

Indication

For the treatment and prevention of osteoporosis in postmenopausal women.

Associated Conditions
Bone Metastases, Hypercalcemia of Malignancy, Osteoporosis
Clinical Trials
Related News

Efficacy and Safety of Oral Ibandronate in Patients of Liver Cirrhosis With Hepatic Osteodystrophy.

Not Applicable
Not yet recruiting
Conditions
Hepatic Osteodystrophy
Liver Cirrhosis
Interventions
First Posted Date
2023-09-01
Last Posted Date
2023-09-01
Lead Sponsor
Institute of Liver and Biliary Sciences, India
Target Recruit Count
80
Registration Number
NCT06022237
Locations
🇮🇳

Institute of Liver & Biliary Sciences (ILBS), New Delhi, Delhi, India

Use of Ibandronate in Diabetic Patients

Not Applicable
Completed
Conditions
Type 2 Diabetes
Osteoporosis, Postmenopausal
Interventions
First Posted Date
2022-03-04
Last Posted Date
2022-03-04
Lead Sponsor
Yeouido St. Mary's Hospital
Target Recruit Count
121
Registration Number
NCT05266261
Locations
🇰🇷

Yeouido St.Mary's Hospital, Seoul, Korea, Republic of

Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without Ibandronate

Phase 2
Completed
Conditions
Osteoporosis, Postmenopausal
Interventions
Dietary Supplement: Coral Complex 3
Dietary Supplement: Vitamin D3
First Posted Date
2020-03-25
Last Posted Date
2024-05-09
Lead Sponsor
Columbia University
Target Recruit Count
60
Registration Number
NCT04321837
Locations
🇦🇲

Osteoporosis Center of Armenia, Yerevan, Armenia

Efficacy of Oral Ibandronate in Osteoporosis

Phase 2
Recruiting
Conditions
Osteoporosis
Interventions
Drug: Oral Ibandronate and Vitamin D
First Posted Date
2017-06-14
Last Posted Date
2021-09-21
Lead Sponsor
Shinshu University
Target Recruit Count
100
Registration Number
NCT03186131
Locations
🇯🇵

Yukio Nakamura, Matsumoto, Nagano, Japan

A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versus Placebo

Phase 4
Completed
Conditions
Osteoporosis
First Posted Date
2016-10-31
Last Posted Date
2016-10-31
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
100
Registration Number
NCT02948881
Locations
🇺🇸

GSK Investigational Site, Duncansville, Pennsylvania, United States

Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma

Phase 3
Terminated
Conditions
Multiple Myeloma
Interventions
First Posted Date
2016-04-15
Last Posted Date
2016-07-22
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
89
Registration Number
NCT02739594

A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer

Phase 3
Completed
Conditions
Pain; Bone Neoplasms; Neoplasm Metastasis
Interventions
First Posted Date
2016-03-23
Last Posted Date
2016-03-23
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
334
Registration Number
NCT02716792

Study of Oral Bisphosphonate for Osteopenic Women Treated With Adjuvant Aromatase Inhibitors

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: Placebo
First Posted Date
2015-11-30
Last Posted Date
2019-10-22
Lead Sponsor
Azienda Ospedaliero-Universitaria Careggi
Target Recruit Count
171
Registration Number
NCT02616744
Locations
🇮🇹

Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia

Phase 4
Completed
Conditions
Postmenopausal Osteoporosis
Interventions
First Posted Date
2015-11-13
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1711
Registration Number
NCT02604836

A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis

Phase 4
Completed
Conditions
Post Menopausal Osteoporosis
Interventions
First Posted Date
2015-11-06
Last Posted Date
2016-03-09
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
308
Registration Number
NCT02598934
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy